66

DAFTAR PUSTAKA

1. American Cancer Society. Cancer Facts & Figures 2013Atlanta, Ga:

American Cancer Society; 2013;5

2. Henley S.J, Singh S, King J, Wilson R, Ryeerson B, invasive cancer

Incidence – United States,2010. Center for Disease Control and

Prevention.2014.(63).12.253-258.

3. Pusat data dan informasi depkes RI. Profil kesehatan Indonesia

2008.Jakarta: Departemen kesehatan republik Indonesia

4. Profil Kesehatan Kota Semarang tahun 2009. Semarang: Dinas kesehatan

kota Semarang

5. Sarjadi, Trihartini, Pawitra I. Insiden kanker penduduk Semarang tahun

1990-1999. Semarang: Media Medika Indonesiana; 2001:36(1): 87-92

6. National comprehensive cancer network. NCCN Clinical Practice

Guidelines in Oncology (NCCN guidelines) Ver 3.2013. Washington; 2012

7. Pallis AG, Mouzas IA. Adjuvant chemotherapy for colon cancer (Review).

Anticancer research. 2006: 26: 4809-16

8. Johnson PW. A less toxic regimen of 5-fluorouracil and high-dose folinic

acid for advanced gastrointestinal adenocarcinomas. British journal cancer.

1991: 64: 603-5

67

9. Cassidy J, Twelves C, Van Cutsem E, et al: first-line capecitabine therapy

in metastatic colorectal cancer: a favourable safety profile compared with

intravenous 5-fluorouracil/leucoforin.Annals of oncology 2002:13:596-570.

10. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral

natural killer cells in gastric carcinoma. Cancer 2000;88: 577 – 83.

11. Agung BS, Faried A, Arifin MZ, Wiriadisastra K, Ohta T. Herbal Medicine

Isolation, Phaleria macrocarpa for primary glioblastoma multiforme cells.

Ann Epidemiol. 2008;18:708–41.

12. Riwanto I, Budijitno S, Dharmana E, Handojo D, Prasetyo SA, Eko A, et al.

Effect of phaleria macrocarpa supplementation on apoptosis and tumor

growth of C3H mice with breast cancer under treatment with adriamycin-

cyclophosphamide. Int Surg. 2011;96:164–70.

13. Zheng W, Gao X, Chen C, Tan R .Total flavonoids of daphne genkwa root

significantly inhibit the growth and metastasis of Lewis lung carsinoma in

C57BL6 mice.Int Immunopharmacol,2006:7(2): 117-27.

14. Budijitno S, Issakh B, Handojo D, Pudjonarko D, Riwanto I. Pengaruh

ekstrak mahkota dewa (Phaleria macrocarpa) terhadap skor ekspresi perforin

CTL dan sel-NK serta perkembangan massa tumor adenokarsinoma mamma

mencit C3H. M Med Indones J. 2007;42(3):37-40.

15. Sumastuti R, Sonlimar M. Efek sitotoksik ekstrak buah dan daun Phaleria

macrocarpa terhadap sel hepar. Yogyakarta: Farmakologi FK UGM;

2003:1-12.

68

16. Trapani JA. Granzymes: a family of lymphocyte granule serine proteases.

Protein Family Review.Genome Biology 2001:2(12).1-7.

17. Bots M, Madema JP. Granzymes at glance.Journal of cell science.

2006:119.5011-5014.

18. Agoes A. Mahkota dewa (Phaleria macrocarpa [scheff] boerl). In: Tanaman

obat Indonesia buku 2. Salemba Medika. 2010:71-3.

19. Faried, A., Kurnia, D., Faried, L.S., Usman, N., Miyazaki, T., Kato, H.,

Kuwano, H. Anticancer effects of gallic acid isolated from Indonesian

herbal medicine,Phaleria macrocarpa (Scheff.) Boerl on human cancer cell

lines. Int J Oncol. 2007: 30: 605-13.

20. Hiroko D, Teruhiko F, Shino N, Toshihiro K, Kazuo S. Analysis of cell

growth inhibitory effect of cathechin through MAPK in human breast

cancer cell line T47D. International Journal of Oncology. 2002: 21: 1301-5.

21. Kusmardiyani, S., Nawawi, A., Rahmi, K. Isolasi benzofenon dari daun

mahkota dewa [Phaleria macrocarpa (Scheff.) Boerl.]. Acta Pharmaceutica

Indonesia. 2004: 29: 150-2.

22. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer

Statistics 2008. CA Cancer J Clin. 2011: 61: 69-90.

23. Parkin DM, Bray F, Ferlay J: Global Cancer Statistics 2002. CA Cancer J

Clin. 2011:55: 74-6.

24. Sjamsuhidajat R, Natawijana HA, Kartowisastro H. Faktor penyebab dan

resiko kanker usus besar. Semarang: Simposium upaya penemuan

keganasan usus besar secara dini; 19861-5.

69

25. Sinicrope FA, Hart J, Hsu H. Apoptotic and mitotic indices predict survival

rates in lymph node-negative colon carcinoma. Clinical Cancer Research.

1999: 1-5.

26. Wilkinson NW. Adjuvant chemotherapy for colorectal cancer - new

perspective for effective treatment. US gastroenterology review. 2007: 91-3.

27. Gordon PH, Nivatvongs S. 2007. Principles and practice of surgery for the

colon, rectum, and anus. 3rd ed. Informa Healthcare USA: New York. 1:2-

27.

28. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in

colorectal center. CA cancer J clin. 2009: 59: 366-378.

29. Mescher AL. 2010. Junqueira’s basic histology. 12th ed. Indiana: McGraw-

Hill education.5-25.

30. Zinner MJ, Ashley SW. 2011.Tumor of Colon. Maingot’s abdominal

operations. 11th ed. Boston: McGraw-Hill; 23.

31. Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews

JB, et al. 2010. Schwartz’s Principles of Surgery. 9th ed. Houston: McGraw-

Hill.28:733-783.

32. Rosai J. 2011. Rosai and Ackerman’s surgical pathology. 10th ed. Milan:

Mosby, London, UK, Elsevier;.(2) .2116.

33. Hamilton SR, Aaltonen LA. World Health Organization classification of

tumours: Pathology and genetics of tumours of the digestive system. Lyon:

IARC Press.2000:101-142.

70

34. Sobin LH, Wittekind CH. International Union Against Cancer UICC:

Classification of malignant tumours TNM. 7th ed. Oxford: A John Wiley &

Sons Inc. 2009; 27-28.

35. National comprehensive cancer network. NCCN Clinical Practice

Guidelines in Oncology (NCCN guidelines) Ver 3.2013. Washington; 2012

36. Kelompok kerja adenokarsinoma kolorektal Indonesia. Pengelolaan

karsinoma kolorektal: Suatu Panduan Klinis Nasional. Jakarta; 2004:1-51.

37. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC. Adjuvant therapy of

colorectal cancer: Why we still don’t know. JAMA. 1988.259.3571-8.

38. Wilkinson NW. Adjuvant chemotherapy for colorectal cancer - new

perspective for effective treatment. US gastroenterology review. 2007: 91-3.

39. Naito Y, Saito K, Shiiba K, Ohuchi A, Saiqenji K, Naqura H, et al. CD8+ T

cells infiltrated within cancer cells nests as prognostic factor in human

colorectal cancer. Cancer Res. 1998; 58: 3491-4.

40. Ali AA, McMillan DC, Matulka II, McNicol AM, McArdel CS. Tumor T-

lymphocytes subset infiltration and tumour recurrence following curative

resection for colorectal cancer: Eur J Surg Oncol. 2004: 30: 292-5.

41. Kintzios SE, Maria G, Barberaki. Plants that fight cancer.Greece: CRC

Press LLC; 2004:125-7.

42. Abbas A, Lichtman AH, Pillai S. Cellular and molecular immunology. 6thed.

Philadelphia: Elsevier-Saunders; 2007: 4 - 15, 22 - 3, 65 - 80, 81 - 103, 182

- 7, 247 - 53, 258 - 9, 266, 268-9, 279-80, 290-5, 351–55,391-403.

71

43. Gorczynski R, Stanley J. Clinical Immunology. Georgetown, Texas: Landes

Bioscience. 1999: 337:53.

44. Jodi R, Viste, Sherry L, Myers, Singh B,Simko E. Feline mammary

adenocarcinoma: tumor size as a prognostic indicator. Can Vet J. 2002;

43(1).33: 7.

45. Kresno SB. 2003. Imunologi: diagnosis dan prosedur laboratorium edisi ke-

4. Balai Penerbit FKUI. Jakarta.208 : 24.

46. Karnen GB. 2006. Imunologi. 6th ed. Balai Penerbit FKUI. Jakarta. 222:7.

47. Restifo NP, Wunderlich JR. Cancer immunology. In: DeVita VT, Hellman

S, Steven AR. Cancer: principles and practice of oncology. 7th edition.

Philladelphia: Lippincott Williams & Wilkins; 2005: 140 – 58.

48. Killeen A. Principes of Moecular Pathology. New Jersey. Humana Press;

2004;202-207.

49. Berke G, Clark WR. Killer lymphocytes. Dordrecht, Netherland: Springer;

2005. 201 -216

50. Los M, Gibson SB. Apoptotic pathways as targets for novel therapies in

cancer and other diseases. New York: Springer; 2005.375-391

51. Martin AW. Immunohistology of non-Hodgkin lymphoma. In: Dabbs D.

Diagnostic immunohistochemistry 3rd ed. Philadelphia: Elsevier Saunders;

2010: 139 – 40, 167, 179.

52. Kumar, Abbas, Fausto, Mitchell. Robbins basic pathology 8th ed.

Philadelphia: Elsevier Saunders; 2007.

72

53. Trapani JA. Smyth M J. Functional Significance ofthe perforin/ granzyme

cell death pathway. Int J Immunol. 2002; 22 (2) : 735-47.

54. Adrain C, Creagh EM, Martin S J. Caspasecascades in apoptosis. In: Marek

Los, Henning Walczak. Editors. Caspases-their role in cell death and cell

survival. New York: Moleculare Biology Intelligence Unit 24; 2002: 41-51.

55. DenaultJB, Salvesen GS. Caspases: keys in the ignition of cell death. Chem

Rev 2002:102(12): 4489-500.

56. Hendra R, Ahmad S, Oskoueian E, Sukari A, Shukor MY. Antioxidant, anti-

inflammatory and cytotoxicity of Phaleria macrocarpa (Boerl.) Scheff Fruit.

BMC Complementary and Alternative Medicine. 2011: 11: 110

57. Agoes A. Mahkota dewa (Phaleria macrocarpa [scheff] boerl). In: Tanaman

obat Indonesia buku 2. Salemba Medika. 2010:71-3.

58. Hendra R, Ahmad S, Oskoueian E, Sukari A, Shukor MY. Antioxidant, anti-

inflammatory and cytotoxicity of Phaleria macrocarpa (Boerl.) Scheff Fruit.

BMC Complementary and Alternative Medicine. 2011:11:110.

59. Wenzel U, Daniel H. Polyphenols and gene expression. In: Daayf F,

Lattanzio V, editors. Recent advances in polyphenols research. West

Sussex: Blackwell Publishing Ltd; 2008: 363-68.

60. Han X, Shen T, Lou H. Dietary Polyphenos and Their Biologica

Significance.Int. J. Mol. Sci.2007;8,950-988.

61. Bassalion, J.P., Scievella, A.R., dan Burns, E., Molec. Pharmacol., 56,

1999:359 – 369.

73

62. Jonker D, Spithoff K, Maroun J; Gastrointestinal cancer disease site group.

Adjuvant systemic chemotherapy for stage II and III colon cancer following

complete resection. Toronto: Cancer care Ontario; 2008 Apr 17 [In review

2011 Sep]. Program in evidence-based care evidence-based series : 2-29.

63. Andre T, O’neil BH, Meyerhardt JA. Stage III Kolon Cancer : What works,

what doesn’t and why, and what’s next. American Society of Clinical

Oncology. 2012:10:223-30.

64. Govindan R, Arquette MA, Washington manual of oncology. Washington:

Lippincott Williams and Wilkins; 2002:192-202.

65. Chu E, DeVita VT. Physicians’ cancer chemotherapy drug manual 2010.

Massachusetts: Jones and Bartlett Publishers; 2010:183-8.

66. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et

al. Leucovorin and fluorouracil without oxaliplatin as first-line treatment in

advanced colorectal cancer. American society of clinical oncology. Journal

of clinical oncology. 2000:18;16.

67. 1,2 Dimethylhydrazine. IARC Monographs Vol 71. 1087: 958-61

68. Joseph CA, Woo YT, Argus MF. Chemical of cancer. London: Academic

Press; 1982:350-93.

69. Nauss KM, Lockniskir M, Pavlina T, Newbere PM. Morphology and

distribution of 1,2-Dimethylhidrazine-induced colon tumor and their

relationship to gut-associated lymphoid tissue in the rat. J Natl Cancer Inst.

1984:73: 915-24.

74

70. Samiasih A. Perbedaan ekspresi VEGF sel adenokarsinoma kolorektal tikus

Sprague Dawley dengan dan tanpa pemberian ekstrak Phyllantus niruri.

Semarang: Magister ilmu biomedik program pasca sarjana Universitas

Diponegoro; 2010;24-33.

71. D. C. Bicknell, A . Rowan, and W. F. Bodmer, “ ß2Mi crog lobulin gene

mutations: a study of established colorectal cell lines and fresh tumors,”

Proceeding s of the Nat i onal Ac ade my of Sc ie nces of the United States

of Ame r i ca: 1994.vol. 91, 4751–4755

72. Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, et al. Comprehensive

analysis of the percentage of surface receptors and cytotoxic granules

positive natural killer cells in patients with pancreatic cancer, gastric cancer,

and colorectal cancer. J Transl Med (2013) 11:262.10.1186/1479-5876-11-

262

75

LAMPIRAN

LAMPIRAN 1 : PERHITUNGAN DOSIS KONVERSI

1,2 Dimethylhidrazine

Dosis 30 mg/kgBB/minggu

Berat 20 gram = 6mg/ekor/minggu

Jumlah pemberian 16 kali

TOTAL = 16 kali x 6 mg x 40 ekor = 3.840 mg

5FU-Leucovorin (Rosswell Park Regiment)

Dosis pemberian kemoterapi (Konstanta konversi = 0.018)

BSA Tikus : BB Tikus = 200 gram = 0,2 kg - Panjang Badan Tikus : 20 cm

BSA = 10.5 (wt. in grams)2/3 = 0.03 m2

Dosis Leucovorin pada Tikus = 500 mg/m2 x 0.018 x 0.03 m2 = 0.27 mg

Dosis 5FU pada Tikus = 500 mg/m2 x 0.018 x 0.03 m2 = 0.27 mg

P. macrocarpa

Dosis ekstrak = 0.495 mg/hari

Konsentrasi larutan = 0.495 mg/ml

Jumlah tikus = 16 ekor

Lama perlakuan = 49 hari

Kebutuhan ekstrak Phaleria macrocarpa = 0.495 mg/ekor/hr x 16 ekor x 49 hari = 388.08 mg =784 cc

76

LAMPIRAN 2. HASIL PENGAMATAN DENSITAS SEL NK DAN EKSPRESI

GRANZYM B

Tabel 9: Tabulasi data densitas Sel NK

Kel La1 La2 La3 La4 La5 Rataa Lb1 Lb2 Lb3 Lb4 Lb5 ratab rataNK

K 1 6 4 6 5 6 5.4 6 6 6 5 6 5.8 5.6

K 2 5 6 5 4 6 5.2 6 4 6 5 6 5.4 5.3

K 3 6 6 5 3 5 5 5 6 6 6 5 5.6 5

K 4 4 4 5 6 5 4.8 4 5 7 6 5 5.4 5.1

K 5 4 5 4 5 4 4.4 5 4 4 5 4 4.4 4.4

K 6 6 7 6 6 7 6.4 7 6 5 6 7 6.2 6.3

P1 1 10 7 10 10 8 9 8 9 10 10 8 9 9

P1 2 8 9 8 6 10 8.2 9 9 8 7 10 8.6 8.4

P1 3 8 8 8 8 8 8 9 8 7 8 8 8.8 8

P1 4 8 8 10 8 8 8.4 8 9 9 10 9 9 8.7

P1 5 9 10 8 8 10 9 8 10 8 8 9 8.6 8.8

P1 6 10 9 10 8 10 9.4 10 9 9 8 10 9.2 9.3

Tabel 10: Tabulasi data ekspresi granzym B

Kel La1 La2 La3 La4 La5 Rataa Lb1 Lb2 Lb3 Lb4 Lb5 ratab rataGR

K 1 10 8 11 10 8 9.4 10 9 10 9 9 9.4 9.4

K 2 12 12 11 9 10 10.8 11 12 10 11 10 10.8 10.8

K 3 12 10 10 8 10 10 11 10 10 9 10 10 10

K 4 10 10 10 12 12 10.8 11 10 11 11 11 10.8 10.8

K 5 9 11 11 10 9 10 9 11 11 10 9 10 10

K 6 11 9 10 11 11 10.4 12 9 10 11 10 10.4 10.4

P1 1 14 12 8 10 13 11.4 14 11 9 11 12 11.4 11.4

P1 2 12 10 10 14 10 11.2 12 11 10 13 10 11.2 11.2

P1 3 10 12 12 10 10 10.8 11 11 12 10 10 10.8 10.8

P1 4 12 10 13 10 11 11.2 12 12 13 12 11 11.2 11.2

P1 5 12 10 14 12 11 11.8 12 11 13 11 12 11.8 11.8

P1 6 13 12 10 12 12 11.8 12 12 11 13 11 11.8 11.8

77

LAMPIRAN 3. FOTO PENELITIAN

Gambar 12. Gambar hewan coba sedang diinduksi 1,2-dimethylhidrazine (kanan)

Gambar 13. Gambar hewan coba sedang mendapat perlakuan (kiri)

Gambar 14. Gambaran makroskopis adenokarsinoma kolorektalyang sudah diisolasi ( kanan dan kiri)

78

LAMPIRAN 4. ANALISIS STATISTIK

SEL NATURAL KILLER

Case Processing Summary

Cases

Included Excluded Total

N Percent N Percent N Percent

Sel_NK * Kelompok 12 100.0% 0 .0% 12 100.0%

EXPLORE

RATA DENSITAS SEL_NK

Kelompok N Mean Median Minimum Maximum Sum Variance Std. Deviation

Kontrol 6 5.283 5.200 4.4 6.3 31.7 .406 .6369

P1 6 8.700 8.750 8.0 9.3 52.2 .208 .4561

Total 12 6.992 7.150 4.4 9.3 83.9 3.463 1.8608

Tests of Normality

Kelompok

Kolmogorov-Smirnova Shapiro-Wilk

Statistic df Sig. Statistic Df Sig.

Sel_NK Kontrol .162 6 .200* .977 6 .936

P1 .167 6 .200* .987 6 .980

a. Lilliefors Significance Correction

*. This is a lower bound of the true significance.

Test of Homogeneity of Variance

Levene Statistic df1 df2 Sig.

Sel_NK Based on Mean .344 1 10 .570

Based on Median .328 1 10 .579

Based on Median and with

adjusted df

.328 1 8.765 .581

Based on trimmed mean .344 1 10 .571

79

RATA –RATA DENSITAS SEL NK KELOMPOK KONTROL

RATA –RATA DENSITAS SEL NK KELOMPOK PERLAKUAN

.

80

BOX PLOT KELOMPOK KONTROL DAN PERLAKUAN

UJI KOMPARASI DENGAN INDEPENDENT T TESTLevene's Test for Equality of Variances t-test for Equality of Means

95% Confidence Interval of the

Difference

F Sig. t dfSig. (2-tailed)

Mean Difference

Std. Error Difference Lower Upper

Sel_NK Equal variances assumed .344 .570 -10.683 10 .000 -3.4167 .3198 -4.1292 -2.7041

Equal variances not assumed -10.683 9.060 .000 -3.4167 .3198 -4.1394 -2.6939

81

GRANZYM B

Case Processing Summary

Cases

Included Excluded Total

N Percent N Percent N Percent

Granzyme_B * Kelompok 12 100.0% 0 .0% 12 100.0%

EXPLORE

.

Tests of Normality

Kelompok

Kolmogorov-Smirnova Shapiro-Wilk

Statistic df Sig. Statistic df Sig.

Granzyme_B Kontrol .185 6 .200* .913 6 .459

P1 .201 6 .200* .912 6 .452

a. Lilliefors Significance Correction

*. This is a lower bound of the true significance.

Test of Homogeneity of Variance

Levene Statistic df1 df2 Sig.

Granzyme_B Based on Mean .952 1 10 .352

Based on Median .899 1 10 .365

Based on Median and with

adjusted df

.899 1 9.648 .366

Based on trimmed mean .950 1 10 .353

RATA EKSPRESI GRANZYM B

Kelompok N Mean Median Minimum Maximum Sum Variance Std. Deviation

Kontrol 6 10.233 10.200 9.4 10.8 61.4 .295 .5428

P1 6 11.367 11.300 10.8 11.8 68.2 .151 .3882

Total 12 10.800 10.800 9.4 11.8 129.6 .553 .7435

82

RATA –EKSPRESI GRANZYM B KELOMPOK KONTROL

RATA –EKSPRESI GRANZYM B KELOMPOK PERLAKUAN

83

BOX PLOT KELOMPOK KONTROL DAN PERLAKUAN

UJI KOMPARASI DENGAN INDEPENDENT T TESTLevene's Test for Equality of

Variances t-test for Equality of Means

95% Confidence

Interval of the Difference

F Sig. t dfSig. (2-tailed)

Mean Difference

Std. Error Difference Lower Upper

Granzyme_B Equal variances assumed .952 .352 -4.160 10 .002 -1.1333 .2724 -1.7404 -.5263

Equal variances not assumed

-4.160 9.053 .002 -1.1333 .2724 -1.7491 -.5176

UJI KORELASI DENGAN UJI PEARSON

Sel_NK Granzyme_B

Sel_NK Pearson Correlation 1 .819**

Sig. (2-tailed) .001

N 12 12

Granzyme_B Pearson Correlation .819** 1

Sig. (2-tailed) .001

N 12 12

**. Correlation is significant at the 0.01 level (2-tailed).

84

LAMPIRAN 5. ETHICAL CLEARANCE